Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BG Medicine Inc lowers FY 2014 revenue outlook


Thursday, 14 Aug 2014 08:01am EDT 

BG Medicine Inc:No longer expects FY 2014 revenues to exceed FY 2013 revenues.It is in light of the decrease in year-to-date revenues from a clinical laboratory customer and the lack of predictability of sales relating to independent research studies.Reported revenue of $4.1 mln in FY 2013.FY 2014 revenue of $5.7 mln - Thomson Reuters I/B/E/S. 

Company Quote

0.4836
0.0169 +3.62%
4:00pm EDT